Claims for Patent: 10,905,690

Summary for Patent: 10,905,690

Title:	Treatment of congenital adrenal hyperplasia
Abstract:	CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Inventor(s):	Dimitri E. Grigoriadis
Assignee:	Neurocrine Biosciences Inc
Application Number:	US16/227,127
Patent Claims:	1. A method of treating Congenital Adrenal Hyperplasia (CAH), said method comprising administering to a subject in need thereof an effective amount of a CRF1 receptor antagonist, wherein the CRF1 receptor antagonist is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543), or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the CRF1 receptor antagonist is administered at bedtime. 3. The method of claim 1, wherein the CRF1 receptor antagonist is administered at or before the expected circadian release of ACTH. 4. The method of claim 1, wherein the CRF1 receptor antagonist is administered 3-4 hours before the expected circadian release of ACTH. 5. The method of claim 1, wherein the CRF1 receptor antagonist is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543).